Adverse reactions were manageable with
subcutaneous EPKINLY1

Majority of adverse reactions were mild to moderate (grade 1 or 2)1

 

Most common treatment-related adverse reactions (≥10%, N=157)

 

ADVERSE REACTIONS* ALL GRADES (%) GRADE 3 OR 4 (%)
Cytokine release syndrome 51 2.5
Fatigue§ 29 2.5
Musculoskeletal pain§ 28 1.3
Injection site reactions§ 27 0
Pyrexia 24 0
Abdominal pain§ 23 1.9
Nausea 20 1.3
Diarrhea 20 0
Rash§ 15 0.6
Edema§ 14 1.9
Headache 13 0.6
Vomiting 12 0.6
Decreased appetite 12 0.6
Cardiac arrhythmias§ 10 0.6
  • Serious adverse reactions occurred in 54% of patients (reactions occurring ≥2%: CRS, infections, pleural effusion, febrile neutropenia, fever, and ICANS)1
  • Fatal adverse reactions occurred in 3.8% of patients (1.3% COVID-19, 0.6% hepatotoxicity, 0.6% ICANS, 0.6% myocardial infarction, 0.6% pulmonary embolism)1
  • Most adverse reactions occurred early in treatment (C1-3), and incidence declined after 12 weeks2

*Adverse reactions were graded based on CTCAE Version 5.0.

Only grade 3 adverse reactions occurred.

CRS was graded using ASTCT consensus criteria (Lee et al, 2019).

§Term includes other related terms. See full Prescribing Information.

  • Serious adverse reactions occurred in 54% of patients (reactions occurring ≥2%: CRS, infections, pleural effusion, febrile neutropenia, fever, and ICANS)1
  • Fatal adverse reactions occurred in 3.8% of patients (1.3% COVID-19, 0.6% hepatotoxicity, 0.6% ICANS, 0.6% myocardial infarction, 0.6% pulmonary embolism)1
  • Most adverse reactions occurred early in treatment (C1-3), and incidence declined after 12 weeks2

Low discontinuation rate (3.8%) due to any adverse reaction2

  • Adverse reactions that led to discontinuation included COVID-19, CRS, ICANS, pleural effusion, and fatigue2
  • Dosage interruptions due to an adverse reaction occurred in 34% of patients (reactions occurring ≥3%: CRS, neutropenia, sepsis, and thrombocytopenia)1

ASTCT=American Society for Transplantation and Cellular Therapy; C1-3=cycles 1-3; COVID-19=coronavirus disease of 2019; CRS=cytokine release syndrome; CTCAE=Common Terminology Criteria for Adverse Events; ICANS=immune effector cell-associated neurotoxicity syndrome; NHL=non-Hodgkin lymphoma.

Has your care facility historically managed CRS?

Managing CRS events.
Learn more about dosing modifications for CRS events

VIEW DOSING MODIFICATIONS

Obtain information about CRS with EPKINLY.
Resources are available to learn how to manage these events

EXPLORE CRS EVENTS

Connect with a representative to help
you learn more about EPKINLY

CONTACT A REP

Review the CRS and ICANS events that occurred
in the clinical trial